329 related articles for article (PubMed ID: 25769621)
21. NK cell tolerance of self-specific activating receptor KIR2DS1 in individuals with cognate HLA-C2 ligand.
Pittari G; Liu XR; Selvakumar A; Zhao Z; Merino E; Huse M; Chewning JH; Hsu KC; Dupont B
J Immunol; 2013 May; 190(9):4650-60. PubMed ID: 23554313
[TBL] [Abstract][Full Text] [Related]
22. Donor and recipient HLA/KIR genotypes do not predict liver transplantation outcome.
Moroso V; van der Meer A; Tilanus HW; Kazemier G; van der Laan LJ; Metselaar HJ; Joosten I; Kwekkeboom J
Transpl Int; 2011 Sep; 24(9):932-42. PubMed ID: 21672051
[TBL] [Abstract][Full Text] [Related]
23. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.
Bishara A; De Santis D; Witt CC; Brautbar C; Christiansen FT; Or R; Nagler A; Slavin S
Tissue Antigens; 2004 Mar; 63(3):204-11. PubMed ID: 14989709
[TBL] [Abstract][Full Text] [Related]
24. Influence of KIR and NK Cell Reconstitution in the Outcomes of Hematopoietic Stem Cell Transplantation.
Gao F; Ye Y; Gao Y; Huang H; Zhao Y
Front Immunol; 2020; 11():2022. PubMed ID: 32983145
[TBL] [Abstract][Full Text] [Related]
25. Role of KIRs and KIR ligands in hematopoietic transplantation.
Velardi A
Curr Opin Immunol; 2008 Oct; 20(5):581-7. PubMed ID: 18675345
[TBL] [Abstract][Full Text] [Related]
26. A retrospective analysis to evaluate if KIR B haplotype donors associate with a reduced risk of relapse in patients with haematological malignancies following haploidentical transplantation at the Blood and Bone Marrow Transplant Unit at Hammersmith Hospital ICHNHST.
Byrnes CP; Hastings A; Lacej I; Palanicawandar R; Olavarria E; Anand A
HLA; 2024 Jan; 103(1):e15214. PubMed ID: 37712429
[TBL] [Abstract][Full Text] [Related]
27. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.
Cooley S; Trachtenberg E; Bergemann TL; Saeteurn K; Klein J; Le CT; Marsh SG; Guethlein LA; Parham P; Miller JS; Weisdorf DJ
Blood; 2009 Jan; 113(3):726-32. PubMed ID: 18945962
[TBL] [Abstract][Full Text] [Related]
28. Human Leukocyte Antigen-C Genotype and Killer Immunoglobulin-like Receptor-Ligand Matching in Korean Living Donor Liver Transplantation.
Lee H; Park KH; Park HS; Ryu JH; Lim J; Kim Y; Na GH; Kim DG; Oh EJ
Ann Lab Med; 2017 Jan; 37(1):45-52. PubMed ID: 27834065
[TBL] [Abstract][Full Text] [Related]
29. Inhibitory killer cell immunoglobulin-like receptor (iKIR) mismatches improve survival after T-cell-repleted haploidentical transplantation.
Bastos-Oreiro M; Anguita J; Martínez-Laperche C; Fernández L; Buces E; Navarro A; Pascual C; Pérez-Corral A; Balsalobre P; Muñoz C; Kwon M; Serrano D; Perez-Martinez A; Buño I; Gayoso J; Díez-Martín JL
Eur J Haematol; 2016 May; 96(5):483-91. PubMed ID: 26133015
[TBL] [Abstract][Full Text] [Related]
30. Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation.
Kröger N; Binder T; Zabelina T; Wolschke C; Schieder H; Renges H; Ayuk F; Dahlke J; Eiermann T; Zander A
Transplantation; 2006 Oct; 82(8):1024-30. PubMed ID: 17060849
[TBL] [Abstract][Full Text] [Related]
31. The impact of recipient HLA-Cw and donor killer immunoglobulin-like receptor genotyping on the outcome of patients receiving HLA-matched sibling donor hematopoietic stem cell transplantation for myeloid malignancies.
Wang H; He Y; Zhai WJ; Wang M; Zhou Z; Zhao YX; Feng SZ; Han MZ
Swiss Med Wkly; 2013; 143():w13717. PubMed ID: 23299929
[TBL] [Abstract][Full Text] [Related]
32. KIR and their HLA Class I ligands: Two more pieces towards completing the puzzle of chronic rejection and graft loss in kidney transplantation.
Littera R; Piredda G; Argiolas D; Lai S; Congeddu E; Ragatzu P; Melis M; Carta E; Michittu MB; Valentini D; Cappai L; Porcella R; Alba F; Serra M; Loi V; Maddi R; Orrù S; La Nasa G; Caocci G; Cusano R; Arras M; Frongia M; Pani A; Carcassi C
PLoS One; 2017; 12(7):e0180831. PubMed ID: 28686681
[TBL] [Abstract][Full Text] [Related]
33. Expression of KIR2DS1 does not significantly contribute to NK cell cytotoxicity in HLA-C1/C2 heterozygous haplotype B donors.
Baltner K; Kübler A; Pal M; Balvociute M; Mezger M; Handgretinger R; André MC
Int Immunol; 2017 Nov; 29(9):423-429. PubMed ID: 29099970
[TBL] [Abstract][Full Text] [Related]
34. Identifying NK Alloreactive Donors for Haploidentical Hematopoietic Stem Cell Transplantation.
Ruggeri L; Mancusi A; Urbani E; Velardi A
Methods Mol Biol; 2016; 1393():141-5. PubMed ID: 27033224
[TBL] [Abstract][Full Text] [Related]
35. Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia.
Cooley S; Weisdorf DJ; Guethlein LA; Klein JP; Wang T; Marsh SG; Spellman S; Haagenson MD; Saeturn K; Ladner M; Trachtenberg E; Parham P; Miller JS
J Immunol; 2014 May; 192(10):4592-600. PubMed ID: 24748496
[TBL] [Abstract][Full Text] [Related]
36. Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia.
Schetelig J; Baldauf H; Koster L; Kuxhausen M; Heidenreich F; de Wreede LC; Spellman S; van Gelder M; Bruno B; Onida F; Lange V; Massalski C; Potter V; Ljungman P; Schaap N; Hayden P; Lee SJ; Kröger N; Hsu K; Schmidt AH; Yakoub-Agha I; Robin M
Front Immunol; 2020; 11():584520. PubMed ID: 33542712
[TBL] [Abstract][Full Text] [Related]
37. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation.
Verheyden S; Schots R; Duquet W; Demanet C
Leukemia; 2005 Aug; 19(8):1446-51. PubMed ID: 15973456
[TBL] [Abstract][Full Text] [Related]
38. The beneficial impact of missing KIR ligands and absence of donor KIR2DS3 gene on outcome following unrelated hematopoietic SCT for myeloid leukemia in the Chinese population.
Wu GQ; Zhao YM; Lai XY; Luo Y; Tan YM; Shi JM; Li L; Zheng WY; Zhang J; Hu XR; Jin AY; He JS; Xie WZ; Ye XJ; Cai Z; Lin MF; Huang H
Bone Marrow Transplant; 2010 Oct; 45(10):1514-21. PubMed ID: 20173784
[TBL] [Abstract][Full Text] [Related]
39. Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation.
McQueen KL; Dorighi KM; Guethlein LA; Wong R; Sanjanwala B; Parham P
Hum Immunol; 2007 May; 68(5):309-23. PubMed ID: 17462498
[TBL] [Abstract][Full Text] [Related]
40. KIR2DS1-mediated activation overrides NKG2A-mediated inhibition in HLA-C C2-negative individuals.
Foley B; De Santis D; Lathbury L; Christiansen F; Witt C
Int Immunol; 2008 Apr; 20(4):555-63. PubMed ID: 18308713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
